| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/05/2009 | CN100522999C Anti-CD20 antibodies and fusion proteins thereof and methods of use |
| 08/05/2009 | CN100522998C Method of stabilizing antibody and stabilized solution-type antibody preparation |
| 08/05/2009 | CN100522995C Cell wall acyl-alanyl-D-isoglutamine derivative and its preparation, medicine composition and use |
| 08/05/2009 | CN100522994C Discrimination between GnRH-I and GnRH-II |
| 08/05/2009 | CN100522242C Artificial proteins with reduced immunogenicity |
| 08/04/2009 | US7569683 Nucleotide sequences coding bacterial cell surface proteins for use in generating monoclonal antibodies for prevention and treatment of infection |
| 08/04/2009 | US7569682 nucleic acid sequences encoding a 30 kD Brachyspira hyodysenteriae lipoprotein; host cell; new locus comprising four genes has now surprisingly been found; swine dysentery |
| 08/04/2009 | US7569678 Protease inhibitor conjugates and antibodies useful in immunoassay |
| 08/04/2009 | US7569676 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs |
| 08/04/2009 | US7569674 Autophilic antibodies |
| 08/04/2009 | US7569673 Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors |
| 08/04/2009 | US7569672 Antibodies that bind to EphA2 and methods of use thereof |
| 08/04/2009 | US7569670 Cytokine zalpha11 ligand fusion proteins |
| 08/04/2009 | US7569666 Polypeptides associated with activatory receptors and their biological applications |
| 08/04/2009 | US7569663 Genetically engineered fusion proteins for use in diagnosis and treatment of cancer, viral infections, autoimmune and alloimmune diseases |
| 08/04/2009 | US7569554 Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents |
| 08/04/2009 | US7569553 Dna bacteria; activate lymphocytes; nucleotide sequences; antigens; administering cytokines |
| 08/04/2009 | US7569552 Attenuated Salmonella typhimurium bacteria comprising a plasmid encoding a polyubiquinated Fra-1 (Fos-related antigen-1) protein and a plasmid encoding Interleukin-18 (IL-18); cancer vaccines |
| 08/04/2009 | US7569544 drug biological conjugates used in the diagnosis, prophylaxis, or treatment of nervous system disorders or lysosomal storage diseases; drug delivery; blood brain barriers |
| 08/04/2009 | US7569541 Malaria vaccine; cyclic peptidomimetics obtainable by these methods which are conformationally constrained due an internal cross-link between 4-aminoproline and glutamine, and having a central (Asn-Pro-Asn-Ala) |
| 08/04/2009 | US7569538 Vaccines against cancer of the upper respiratory tract or anogenital carcinomas, such as cervical cancer, using fragments of the cyclin-dependent kinase inhibitor P16 protein |
| 08/04/2009 | US7569387 Specifically binds an MK61 polypeptide produced by immunizing an animal |
| 08/04/2009 | US7569383 Chimeric flavivirus vectors |
| 08/04/2009 | US7569364 Anti-NGF antibodies and methods using same |
| 08/04/2009 | US7569356 Detecting the presence of a prostate cancer cell expressing a protein SGP28; immunoassay |
| 08/04/2009 | US7569229 Monocyte locomotion inhibitory factor |
| 08/04/2009 | US7569228 Fusion proteins of non-attenuated HIV regulatory/accessory proteins |
| 08/04/2009 | US7569227 Monomeric protein of the TGF-β family |
| 08/04/2009 | US7569226 Alkaline protease from Bacillus sp. (DSM 14392) and washing and cleaning products comprising said alkaline protease |
| 08/04/2009 | US7569225 Immunogenic lipopeptides comprising T-helper and B-cell epitopes |
| 08/04/2009 | US7569224 Mammalian cytokines; receptors; related reagents and methods |
| 08/04/2009 | US7569219 Delivery of recombinant dsRNA phage to eukaryotic cells and tissues, either by direct administration, formulated in lipid or lactide-glycolide copolymer, or by utilizing a bacterial vaccine vector |
| 08/04/2009 | US7569218 Compositions for and methods of using herpes simplex virus glycoprotein D to suppress immune responses |
| 08/04/2009 | US7569217 Porcine adenovirus E1 and E4 regions |
| 08/04/2009 | US7569209 Using procalcitonin concentration as diagnostic tool in detection and evaluation of systemic infection |
| 08/04/2009 | CA2365281C Human antibodies that bind human il-12 and methods for producing |
| 08/04/2009 | CA2247009C Cryptic peptides and method for their identification |
| 08/04/2009 | CA2194673C A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
| 07/30/2009 | WO2009094551A1 Ferroportin antibodies and methods of use |
| 07/30/2009 | WO2009094391A1 Optimized cd40 antibodies and methods of using the same |
| 07/30/2009 | WO2009094387A1 Compositions and methods for inducing tumor resistance |
| 07/30/2009 | WO2009094273A2 Compositions and methods for adoptive and active immunotherapy |
| 07/30/2009 | WO2009094006A2 Bordetella outer-membrane protein antigens and methods of making and using the same |
| 07/30/2009 | WO2009093998A1 NATURALLY OCCURING IgM ANTIBODIES THAT BIND LYMPHOCYTES |
| 07/30/2009 | WO2009093605A1 Anti-canine periodontal disease composition |
| 07/30/2009 | WO2009093143A2 Therapeutic vaccines |
| 07/30/2009 | WO2009093138A1 Humanized antibodies specific for von willebrand factor |
| 07/30/2009 | WO2009093072A1 Vaccine composition |
| 07/30/2009 | WO2009093014A2 Vaccines |
| 07/30/2009 | WO2009093007A2 Immune modulation by regioselectively modified glycosides |
| 07/30/2009 | WO2009092611A1 Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors |
| 07/30/2009 | WO2009092396A1 Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors |
| 07/30/2009 | WO2009092383A2 Products and methods to prevent infection |
| 07/30/2009 | WO2009076170A3 Combinations of therapeutic agents for treating cancer |
| 07/30/2009 | WO2009071892A3 Method for the detection of dead and dying cells |
| 07/30/2009 | WO2009064854A3 Humanized antibodies against tl1a |
| 07/30/2009 | WO2009063222A3 Solid compositions |
| 07/30/2009 | WO2009025759A8 Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof |
| 07/30/2009 | WO2008154638A8 Antagonists of the receptor for advanced glycation end-products (rage) |
| 07/30/2009 | WO2008150814A8 Methods for production and uses of multipotent cell populations |
| 07/30/2009 | WO2008145754A3 Ligands of hvem for treating hematologic malignancies and autoimmune diseases |
| 07/30/2009 | WO2008134445A8 Platelet activation receptor clec-2: compositions and uses thereof |
| 07/30/2009 | WO2008127975A3 Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis |
| 07/30/2009 | WO2008116032A8 Compositions and methods for inhibiting tumor cell growth |
| 07/30/2009 | WO2008040155A8 Oral recombinant helicobacter pylori vaccine and preparing method thereof |
| 07/30/2009 | WO2007137591A8 Hiv vaccine |
| 07/30/2009 | WO2007118431A8 Use of trap protein as active ingredient for manufacturing a medicament for the treatment of staphylococcus aureus infection |
| 07/30/2009 | WO2007104263A8 An enhancin of hepatitis b virus vaccine and its gene |
| 07/30/2009 | WO2007101254A8 Compositions and methods for the treatment of immune system disorders |
| 07/30/2009 | WO2007092772A8 Protein formulations |
| 07/30/2009 | US20090192434 Method and means for treating inflammatory bowel disease |
| 07/30/2009 | US20090192293 Antibodies to non-functional p2x7 receptor |
| 07/30/2009 | US20090192292 Murine zcytor17 ligand polypeptides and polynucleotides |
| 07/30/2009 | US20090192109 Compositions for diagnosis and therapy of diseases associated with aberrant expression of Kremen and/or Wnt |
| 07/30/2009 | US20090192088 Vascular Endothelial Growth Factor 2 |
| 07/30/2009 | US20090191572 Imaging, diagnosis and treatment of disease |
| 07/30/2009 | US20090191536 Rabbit monoclonal antibodies to hepatitis B surface antigens and methods of using the same |
| 07/30/2009 | US20090191268 Allergy vaccines |
| 07/30/2009 | US20090191261 Antibody fragment-targeted immunoliposomes for systemic gene delivery |
| 07/30/2009 | US20090191259 Efficient liposomal encapsulation |
| 07/30/2009 | US20090191255 Bmp-1 procollagen c-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders |
| 07/30/2009 | US20090191253 Use of K-252a and Kinase Inhibitors for the Prevention or Treatment of HMGB1-Associated Pathologies |
| 07/30/2009 | US20090191242 Novel homeopathic strain comprising a nosode from a protozoon of the genus trypanosoma |
| 07/30/2009 | US20090191241 Method and compositions for immunization with the pseudomonas v antigen |
| 07/30/2009 | US20090191240 Flavivirus Vaccines |
| 07/30/2009 | US20090191239 Recombinant infectious laryngotracheitis virus and uses thereof |
| 07/30/2009 | US20090191238 Method for producing yeast expressed HPV types 6 and 16 capsid proteins |
| 07/30/2009 | US20090191237 Methods and reagents for vaccination which generate A CD8 T cell immune response |
| 07/30/2009 | US20090191236 comprises claimed amino acid sequence or an immunogenic fragment thereof wherein the protein elicits production of antibodies that interfere with invasion by Babesia bovis into erythrocytes |
| 07/30/2009 | US20090191235 Conformationally stabilized hiv envelope immunogens and triggering hiv-1 envelope to reveal cryptic v3-loop epitopes |
| 07/30/2009 | US20090191234 Vaccine |
| 07/30/2009 | US20090191233 Influenza antigen delivery vectors and constructs |
| 07/30/2009 | US20090191232 Combination therapy for the treatment of tumors |
| 07/30/2009 | US20090191231 Prevention and treatment of amyloidogenic disease |
| 07/30/2009 | US20090191230 Cascade |
| 07/30/2009 | US20090191229 Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus |
| 07/30/2009 | US20090191228 Immunogenic compositions capable of activating T-cells |
| 07/30/2009 | US20090191227 Compositions and Methods for Enhancing Immune Responses to Vaccines |
| 07/30/2009 | US20090191226 Adjuvant formulation comprising a submicron oil droplet emulsion |
| 07/30/2009 | US20090191225 Fusion proteins; homogeneous purity, and unaltered affinity, and can be produced in high yields without the requirement of extensive purification; stable in serum to allow in vivo applications |